profit from every $100 of sales.
$0$100
XOMA Royalty
We have no price for XOMA Royalty since 21 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$40.17+0.00% today
+10.3% since Oct 10, 25
1-year low $22.891-year high $45.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $22.39 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What XOMA Royalty sold, what it kept, and what it did with the cash.
Sales went from $6.03 million in 2022 to $11.7 million in 2025, with $31.7 million of profit last year.
SalesProfit
XOMA Royalty vs. similar companies
XOMA Royalty grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| XOMA Royalty | 22.4× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads XOMA Royalty's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6 | 5 | 10 | 12 | |
| – | – | – | – | |
| -17 | -23 | -40 | 11 | |
| -17 | -39 | -5 | 48 | |
| -17 | -41 | -14 | 32 | |
| -1.98 | -4.04 | -1.65 | 1.46 | |
| – | – | – | – | |
| -288.9% | -493.1% | -391.2% | 97.6% | |
| -283.8% | -858.2% | -135.2% | 272.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 140 | 234 | 221 | 273 |
| Cash | 58 | 153 | 102 | 83 |
| Total debt | 0 | 124 | 119 | 132 |
| Total liabilities | 16 | 146 | 159 | 189 |
| 124 | 89 | 62 | 84 | |
| 11 | 11 | 12 | 18 | |
| -10.9% | -14.9% | -2.5% | 16.4% | |
| -13.8% | -46.0% | -22.3% | 37.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -18 | -14 | 3 | |
| 15 | 0 | 0 | 21 | |
| -28 | -18 | -14 | -18 | |
| Dividends paid | 5 | 5 | 5 | 5 |
| – | 0 | 0 | 17 | |
| 4 | 9 | 10 | 9 |
Valuation
- 22.4×
- 35.7×
- –
- 7.3×
- 60.9×
- –
- 15.9×
- -2.5%
- 4.5%
- 0.0%
Profitability
- 94.3%
- 97.6%
- 272.0%
- 27.5%
- 4.5%
- -3.0%
- 30.2%
- 10.8%
- 4.8%
- 3.3%
Growth
- +24.6%
- –
- +120.9%
- –
- +12.3%
Financial health
- 3.4×
- 1.27
- 48.2%
- 0.9×
- 3.37
- 3.37
- 0.19
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 946
Top 1%of 872
Top 37%of 563
Top 24%of 868
Bottom 28%of 986
What analysts expect
- Average price target
- $53.75
- Range
- $39.00 – $76.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | 0.17 | 0.19 | −10.5% |
| Mar 18, 2026 | 0.12 | -0.13 | +192.3% |
| Nov 12, 2025 | -0.35 | -0.02 | −1,650.0% |
| Aug 13, 2025 | 0.48 | -0.12 | +500.0% |
| May 13, 2025 | 0.06 | -0.26 | +123.1% |
| Mar 17, 2025 | -0.46 | -0.29 | −58.6% |
| Nov 7, 2024 | -0.39 | -0.44 | +11.4% |
| Aug 13, 2024 | -0.28 | -0.26 | −7.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
45No pass
Philip Fisher
64Pass
Peter Lynch
88Pass
Joel Greenblatt
33No pass
Charlie Munger
43No pass
Terry Smith
46No pass
Questions about XOMA Royalty
Is XOMA Royalty a good stock to buy?
A business with weak numbers at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the XOMA Royalty AI analysis
What does XOMA Royalty do?
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It is in Biotechnology.
Does XOMA Royalty pay a dividend?
Yes. In 2025 it paid out $5.47 million in dividends.
Is XOMA Royalty stock halal?
Yes. XOMA Royalty passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
Who are XOMA Royalty's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with XOMA Royalty's.
Prices: daily closes to Jul 21, 2026. Fundamentals: company reports via invest-like data.